Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
Title:
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
Author:
Madhi, Shabir A Koen, Anthonet L Izu, Alane Fairlie, Lee Cutland, Clare L Baillie, Vicky Padayachee, Sherman D Dheda, Keertan Barnabas, Shaun L Bhorat, Qasim Ebrahim Briner, Carmen Aley, Parvinder K Bhikha, Sutika Hermanus, Tandile Horne, Elizea Jose, Aylin Kgagudi, Prudence Lambe, Teresa Masenya, Masebole Masilela, Mduduzi Mkhize, Nonhlanhla Moultrie, Andrew Mukendi, Christian K Moyo-Gwete, Thandeka Nana, Amit J Nzimande, Ayanda Patel, Faeezah Rhead, Sarah Taoushanis, Carol Thombrayil, Asha van Eck, Samuel Voysey, Merryn Villafana, Tonya L Vekemans, Johan Gilbert, Sarah C Pollard, Andrew J Moore, Penny L Kwatra, Gaurav
Appeared in:
The Lancet. HIV
Paging:
Volume 8 () nr. 9 pages e568-e580
Year:
2021
Contents:
Publisher:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license